(-0.06%) 5 466.14 points
(-0.37%) 38 966 points
(0.27%) 17 766 points
(0.26%) $81.04
(-3.23%) $2.67
(-0.91%) $2 309.60
(-0.36%) $28.77
(1.64%) $1 002.60
(0.29%) $0.936
(0.78%) $10.69
(0.37%) $0.791
(-0.19%) $87.33
Live Chart Being Loaded With Signals
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States...
Stats | |
---|---|
本日の出来高 | 656 224 |
平均出来高 | 2.02M |
時価総額 | 0.00 |
EPS | $-0.450 ( Q2 | 2022-08-08 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-25.93 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.378 (0.73%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2022-10-20 | Jain Rita | Sell | 11 600 | Restricted Stock Unit |
2022-10-20 | Herron Jennifer Lyn | Sell | 17 237 | Common Stock |
2022-10-20 | Edwards Thomas A. | Sell | 15 723 | Restricted Stock Unit |
2022-10-20 | Parker Geoffrey M. | Sell | 15 723 | Restricted Stock Unit |
2022-10-20 | Kanaya Susan M | Sell | 90 968 | Restricted Stock Unit |
INSIDER POWER |
---|
-78.69 |
Last 97 transactions |
Buy: 1 451 999 | Sell: 1 420 462 |
ボリューム 相関
ChemoCentryx, Inc. 相関
10 最も正の相関 | |
---|---|
SANB | 0.835 |
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
ChemoCentryx, Inc. 相関 - 通貨/商品
ChemoCentryx, Inc. 財務諸表
Annual | 2021 |
収益: | $32.22M |
総利益: | $31.92M (99.06 %) |
EPS: | $-1.890 |
FY | 2021 |
収益: | $32.22M |
総利益: | $31.92M (99.06 %) |
EPS: | $-1.890 |
FY | 2020 |
収益: | $64.89M |
総利益: | $64.89M (100.00 %) |
EPS: | $-0.840 |
FY | 2019 |
収益: | $35.95M |
総利益: | $0.00 (0.00 %) |
EPS: | $-0.980 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
ChemoCentryx, Inc.
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California. As of October 20, 2022, ChemoCentryx, Inc. operates as a subsidiary of Amgen Inc.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。